My Star
An Asher Barreras original composition. Played at the Arts in Medicine concert at UNM Hospital, Albuquerque, NM, 12/12/12. Steve Seifert, Tenor Sax, Sam Negri, Keyboard, Chad Scheer, Bass, Asher Barreras, Drums.From:JazzizallViews:0 0ratingsTime:05:13More inMusic
Excerpt from:
Obesity Week - Big Love
uOttawa Medicine Year II - Obesity Week Project Jonathan Blankenstein Gregory Drozdzal Taylor Ferrier Vashti King Nischal Ranganath Brianna Ryman Alyssa Smith Michael WangFrom:flyingduckieViews:6 0ratingsTime:03:13More inEducation
See original here:
On Green Dolphin Street (Cover)
Our cover of On Green Dolphin Street, at the "Arts in Medicine" concert at UNM Hospital, Albuquerque, NM, 12/12/12. Steve Seifert, Tenor Sax, Sam Negri, Keyboard, Chad Scheer, Bass, and Asher Barreras, DrumsFrom:JazzizallViews:1 0ratingsTime:04:06More inMusic
Here is the original post:
Myofascial Release for Rectus Femoris and hamstrings
John Gibbons a registered Sports Osteopath and lecturer in sports medicine is demonstrating Active release techniques (ART) or Soft tissue Release (STR) for the Rectus Femoris and Iliotibial band (IT Band). If you are interested in attending one of John #39;s Certified Physical therapy CPD Courses at the iconic venue of Oxford University look on: http://www.johngibbonsbodymaster.co.ukFrom:John GibbonsViews:4 0ratingsTime:05:03More inEducation
Link:
Myofascial Release for Rectus Femoris and hamstrings - Video
The American College of Preventive Medicine (ACPM) has announced a partnership with the Ardmore Institute of Health to form an expert steering committee to develop a framework, based on established physician competencies, which would facilitate and advance the adoption of lifestyle medicine into clinical practice.
Washington, DC (PRWEB) December 12, 2012
With the enormous potential effects of health behavior change on mortality, morbidity, and health care costs, the motivation for embracing the concept of lifestyle medicine is clear, explained Miriam Alexander, MD, MPH, FACPM, President of ACPM. We have a consensus set of competencies; now we need a blueprint for developing curricula, practice tools, and advocacy materials, all of which will support physicians in implementing lifestyle medicine best practices.
The panel, which will convene February 20, 2013 at ACPMs Preventive Medicine 2013 conference in Scottsdale, AZ, is charged with identifying a pathway for helping physicians adopt lifestyle medicine in their clinical practice. Panel members, mostly recognized leaders in preventive medicine, bring expertise and perspectives from various workplace settings and will contribute important stakeholder perspectives, such as clinical practice, academic medicine, public health, health promotion research, health plans and insurance providers, professional medical societies, and corporate employers. The panels efforts will focus on the physician competencies for prescribing lifestyle medicine previously published in JAMA (Lianov L; Johnson M. Physician competencies for prescribing lifestyle medicine. JAMA. 2010; 304(2):202-3). Liana Lianov, MD, MPH, FACPM, ACPMs Public Health and General Preventive Medicine Regent, President of the American College of Lifestyle Medicine, and chair of ACPMs Lifestyle Medicine Task Force, has been tapped to lead the panel. This group of thought leaders will explore multiple aspects of lifestyle medicine practice and policy and deliver a plan for integrating lifestyle medicine into clinical practice, health care delivery systems, and payment/reimbursement models, says Dr. Lianov. The plan will identify ways to empower key stakeholders, from primary care physicians in the trenches to health care delivery systems struggling to adapt to reforms that reward improved outcomes for populations, with proven approaches to reducing risk and preventing and reversing disease burden. Its an exciting undertaking which Im honored to lead.
Funding for the initiative was provided by the Ardmore Institute of Health. We are proud to support this effort which engages the brightest minds in the field to advance the cause of behavioral change, risk reduction, and the prevention and treatment of disease, noted Sid Lloyd, President and CEO of the Ardmore Health Institute. This is an important and timely endeavor, and one that could have significant and lasting impact on our nations healthcare system.
About the American College of Preventive Medicine
Founded in 1954, the American College of Preventive Medicine (ACPM) is a U.S.-based physician organization focused on practice, research, publication, and teaching of evidence-based preventive medicine. As the umbrella society for the specialty of Preventive Medicine and physicians dedicated to prevention, ACPM seeks to improve the health of individuals and populations through evidence-based health promotion, disease prevention, and systems-based approaches to improving health and health care. For more information, visit http://www.acpm.org.
About Ardmore Institute of Health
Ardmore Institute of Health (AIH) is a public charity on a mission to improve the health and vitality of people to live more meaningful lives. Headquartered in Ardmore, OK, AIH makes the journey toward better health as simple, fun and exciting as possible in each product it develops, such as its New York Times best-selling, "The Full Plate Diet."
# # #
View post:
When I was a sophomore in college, my mother unfortunately lost her very short battle with pancreatic cancer, an experience that changed my life forever. During that time I witnessed firsthand the devastating effects caused by the administration of toxic, non-specific treatments which ultimately failed to stop the spread of the cancer, and instead only made my mother extremely sick. Her death, at the young age of 44, profoundly influenced my feelings towards medicine and altered my career path. As a result, I became driven to discover better drugs for treating cancer, with a focus to specifically target diseased cells while leaving healthy tissues unharmed.Thankfully, my passion for developing smarter cancer drugs is shared by many others, and it has been exciting to see the progress made over the years in developing treatments that can be characterized as "personalized medicines". A commonly cited example that demonstrates the impact of personalized medicine in cancer is the successful development of the breast cancer drug, Herceptin(R), which specifically targets aggressive HER2-positive breast cancer. Importantly, before this medication was developed, women with HER2-expressing breast cancer were less responsive to standard treatments. Now, however, treatment with Herceptin in combination with chemotherapy has amazingly been shown to reduce the recurrence rate of this type of cancer by 52 percent.Building on Biomarkers: Companion DiagnosticsA biomarker is a unique trait of a disease, such as genetic marker or overexpressed protein like HER2. Developing a medicine that targets a specific biomarker can have a positive effect on patient outcome, but this approach is only one part of the therapeutic equation. To truly fulfill the promise of personalized medicine, there must also be a tool available for identifying those patients bearing that biomarker. An agent of this type is called a companion diagnostic. The outcome of this type of test should enable the right drug to be administered, to the right person, at the right time. In this manner, a companion diagnostic helps to identify those patients that may benefit from a given targeted treatment while at the same time identifying patients that will likely not benefit from therapy. Related to the example above, such a test is available to determine if a patient has HER2-positive breast cancer, and it is performed before Herceptin is prescribed.Recently, due to the benefits realized from biomarker testing, interest in developing companion diagnostics has surged. The FDA is very supportive of the development of these patient-selective tests. In fact, one companion diagnostic was approved this year and two within the same month last year to accompany Pfizer's targeted drug for lung cancer, Xalkori(R), and Roche's personalized therapeutic for melanoma, Zelboraf(R). Importantly, Roche stated that it aims to have 60 percent of its drugs in development to be accompanied by some form of a companion test, an indication that, like the FDA, the pharmaceutical industry is also embracing the continued development of companion diagnostic agents.There are many reasons for the significant interest in this space that stem from the benefits of identifying patients with companion diagnostics. For example, in the area of cancer, where development of these agents is most advanced, significant delay of tumor growth and increased survival rates have been demonstrated in patients that were preselected using a companion diagnostic. Having the ability to determine whether a patient may or may not respond to a given treatment enables the selection of the best medicine for that individual, without wasting precious time with trial and error approaches.It is precisely this advantage that allows clinical trials to be conducted in a specific patient population, which can decrease the size and related cost of these studies. Lower costs may allow drug developers to use such savings to invest in additional areas of disease research. Furthermore, smaller clinical trial size means that studies can be conducted more quickly, which could accelerate the arrival of these treatments to the market and broaden access to patients. Collectively, these conserved resources translate into savings for the entire healthcare system, which is an important benefit as rising healthcare costs are a significant issue for our nation.It is worth noting that a recent paper published in the New England Journal of Medicine showed that the genetic characteristics of a tumor, such as biomarker expression, can and often do change over time. Thus, in contrast to conventional companion diagnostics that typically utilize tissue samples obtained through biopsy (especially those performed on archived tissue), additional benefits are found with the use of companion diagnostics that are based on whole-body imaging. Results obtained from non-invasive, real-time imaging methodology, therefore, provide the most up-to-date biomarker information possible to inform treatment decision making. But, regardless of the method employed, the impact of patient selection can be substantial.A New ApproachAt Endocyte, we have seen this patient-selective approach translate into positive clinical results. The technology we're developing consists of targeted therapeutics called small molecule drug conjugates, or SMDCs. Each of these novel compounds consists of a high affinity, cell-specific targeting molecule (the ligand) that is chemically linked to a potent chemotherapy drug. This yields a highly potent, yet selective therapeutic agent; but, this approach also allows us to easily create a companion diagnostic by simply replacing the chemotherapeutic drug in the SMDC construct with an imaging agent.Vintafolide is our most advanced SMDC in development. This therapeutic binds to the folate receptor, which is a confirmed biomarker expressed on many human cancers, including ovarian, lung, breast and colon. Vintafolide's companion diagnostic imaging agent (etarfolatide) is designed to identify cancer patients that have high levels of the folate receptor expression, which is the exact population of patients expected to respond to this drug.In a previous clinical trial in patients with platinum-resistant ovarian cancer, women identified as "FR-positive" by etarfolatide and then subsequently treated with vintafolide had significantly delayed tumor growth. Based on these unprecedented results, especially in a patient population that fails to adequately respond to any therapy, both etarfolatide and vintafolide are being considered for conditional approval in Europe. This could mean that patients would have access to these agents much sooner than expected. Overall, this exciting opportunity would never have been possible if our companion diagnostic agent was not used to select the right patient population to treat with vintafolide in our clinical trials.A Promising FutureBecause of the numerous benefits companion diagnostics hold for patients, physicians, drug developers and our healthcare system, their continued development and use will only increase in the future. Regulatory agencies worldwide are also embracing this approach, and they continue to encourage drug developers to pursue this path for the treatment of all types of diseases. As the number of companion diagnostics in development continues to grow, we are moving closer each day to truly fulfilling the promise of personalized medicine. Follow Scientific American on Twitter @SciAm and @SciamBlogs.Visit ScientificAmerican.com for the latest in science, health and technology news. 2012 ScientificAmerican.com. All rights reserved.
Read the original post:
Advancing the Promise of Personalized Medicine: Companion Diagnostics
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--
MEDNAX, Inc., (MD) today announced the acquisition of a maternal-fetal medicine physician practice based in Lithia Springs, Georgia. The practice will become part of MEDNAXs Pediatrix Medical Group division.
Raj K. Bansal, M.D., P.C., was established in 2002 and is a private practice that consists of one maternal-fetal medicine physician and eight clinical and administrative support staff who provide care to expectant mothers, including the management of high-risk and complicated pregnancies, throughout the Atlanta area. The practice provides maternal-fetal services at five area hospitals, including Wellstar Cobb Hospital, Wellstar Douglas Hospital, Wellstar Kennestone Hospital, Piedmont Hospital and Atlanta Medical Center.
Given the changing and uncertain healthcare environment, we felt that now is the ideal time to partner with a leading national medical group practice, said Raj Bansal, M.D., who will serve as medical director for the practice. We look forward to experiencing the support of a national administrative infrastructure that allows us the opportunity to spend more time caring for our patients.
Dr. Bansal will now be part of MEDNAX's Pediatrix Medical Group, a national medical group consisting of the nation's leading neonatal, maternal-fetal medicine, pediatric cardiology, and other pediatric specialty physicians.
The practice was acquired for cash and the transaction is expected to be immediately accretive to its earnings. No additional terms of the transaction were disclosed.
With this acquisition, 13 physician group practices have become part of MEDNAX in 2012, seven as part of Pediatrix Medical Group, and six as part of American Anesthesiology.
ABOUT MEDNAX
MEDNAX, Inc. is a national medical group that comprises the nation's leading provider of neonatal, maternal-fetal and pediatric physician subspecialty services as well as anesthesia services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Pediatrix Medical Group, a unit of MEDNAX, was founded in 1979 and now includes neonatal physicians who provide services at more than 300 neonatal intensive care units, who collaborate with affiliated maternal-fetal medicine, pediatric cardiology and pediatric critical care physician subspecialists to provide a clinical care continuum. Pediatrix is also the nation's largest provider of newborn hearing screens. In 2007, MEDNAX expanded into anesthesia services. Today, American Anesthesiology includes more than 1,250 anesthesiologists and advanced practitioners who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. MEDNAX, through its affiliated professional corporations, employs more than 1,925 physicians in 34 states and Puerto Rico. Additional information is available at http://www.mednax.com.
Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as believe, hope, may, anticipate, should, intend, plan, will, expect, estimate, project, positioned, strategy and similar expressions, and are based on assumptions and assessments made by MEDNAXs management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAXs most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled Risk Factors, as well MEDNAXs current reports on Form 8-K, filed with the Securities and Exchange Commission.
Go here to read the rest:
MEDNAX Announces Acquisition of Maternal-Fetal Medicine Practice in Georgia
NEW YORK, Dec. 12, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Nuclear Medicine Industry http://www.reportlinker.com/p080450/Global-Nuclear-Medicine-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging
This report analyzes the worldwide markets for Nuclear Medicine in US$ Million by the following Product Segments: Gamma Cameras, and PET Scanners. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 43 companies including many key and niche players such as Digirad Corporation, GE Healthcare Plc, Phillips Healthcare, Inc., Positron Corporation, Siemens Medical Solutions USA, Inc., Toshiba Medical Systems Corporation, and Toshiba America Medical Systems, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Gamma Cameras I-3 PET Scanners I-4
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW AND OUTLOOK II-1 Market Snapshots II-1 Nuclear Medicine - An Introduction II-1 Market Witnesses Turbulent Times in Recent Past II-2 Isotope Supply Shock - A Major Factor for Market Decline II-2 Market Rebounds; Brighter Prospects Ahead II-2 Growth Drivers in a Nutshell II-3 Current and Future Analysis II-3 Emerging Markets to Drive Growth; US Still in Spotlight II-4 Susceptibility to Cardiac Disease, Brain Disorders and Cancers Influence Procedure Volumes II-4 Minimal Impact of Recession on the Medical Contrast Media Market II-4
2. TRENDS AND ISSUES II-5 Global Technetium Shortage Eased II-5 Market Shifts to Hybrid Imaging II-5 PET Eats its Way into Conventional Gamma Camera Market II-6 PET-MRI Emerging as a Promising Standard for Imaging Soft Tissue Contrast II-6 High Costs - A Major Threat for Market Growth II-6 Technology Innovations Promise Bright Prospects II-7 New Innovations in the Nuclear Medicine Device Market II-7 SPECT/CT Scanners Drive Nuclear Medicine Equipment Market in North America II-7 Global Nuclear Medicine Market - Historic Statistics II-8 Table 1: Global Gamma Cameras Market (2006): Installed Based in Units by Select Country - USA, Japan, Canada, and UK (includes corresponding Graph/Chart) II-8
Table 2: Global PET Scanners Market (2006): Installed Base in Units by Select Country - USA, Europe, Japan, Germany, Canada, UK, France, Italy, and Belgium (includes corresponding Graph/Chart) II-8
3. COMPETITIVE LANDSCAPE II-9 Competition Overview in Nuclear Medicine Market II-9 Table 3: Leading Players in the Global Gamma Camera Market (2010 & 2011): Percentage Breakdown of Value Sales for Philips Healthcare, Siemens Healthcare, GE Healthcare, and Others (includes corresponding Graph/Chart) II-9
Table 4: Leading Players in the Global PET Scanner Market (2010 & 2011): Percentage Breakdown of Value Sales for Siemens Healthcare, GE Healthcare, Philips Healthcare and Others (includes corresponding Graph/Chart) II-10 Leading Players in the Worldwide Nuclear Medicine Market: A Completive Analysis II-11
Visit link:
Competition-free Environment in School
http://www.SalmonellaPlace.com Competing is a natural behavior, but a lot of times we gain so much more if we create a competition-free environment. This advice can be applied anytime, anywhere, from high school to medical school. Enjoy! Plus, don #39;t forget to SUBSCRIBE for more! Facebook: http://www.facebook.com/salmonellaplace Twitter: http://www.twitter.com/thesalmonella Tumblr: http://www.salmonellaplace.tumblr.comFrom:TheSalmonellaPlaceViews:3 0ratingsTime:03:08More inEducation
Read the rest here:
Sam Gibbons Oral History Interview, Part 12a
Oral history interview with Sam Gibbons, member of the Florida House of Representatives, 1953-1957, and the Florida Senate, 1959-1962. Discusses Martha #39;s cancer, the Ways and Means committee (W M) and procedure, proposed medical school for USF, opposing war in Vietnam, vying for leadership, Nixon and China, energy policies in the 1970s, sugar trade and agriculture, the rise of the SUV.From:USFLibrariesViews:0 0ratingsTime:01:24:34More inEducation
More here:
Bar-Ilan Medical School - "Would you help me"
In January 2010, Bar-Ilan University was unanimously awarded Governmental tender to establish Israel #39;s fifth Faculty of Medicine in the Galilee. This tender was issued as a result of the shortage of medical doctors in Israel and the inferior level of medical services in the Galilee. Bar-Ilan University immediately set out to fulfill its important mission.From:AFBIUViews:2 0ratingsTime:06:50More inEducation
Read more:
Decrease Cancer Risk By Eating Rainbow Of Fruits, Vegetables
Micronutrients in brightly colored produce may help decrease cancer risk. As John Basedow reports, researchers from Harvard Medical School and Brigham Women #39;s Hospital believe carotenoids, the pigments that give fruits and vegetables vibrant colors, have anti-cancer effects. Carrots, spinach and kale are particularly high in carotenoids. Buzz60 is designed for the way we live now. Short, quirky video snacks that are a little sassy, and always smart. Buzz 60 -- and the Buzz60 channel on YouTube - produces all kinds of newsy video clips for web viewers who want more than just repurposed content. Our team is a diverse group of video journalists with dozens of Emmy awards, an authentic sense of humor, and a mandate to connect with viewers every day. Subscribe to our channel: http://www.youtube.com Like us Facebook: http://www.facebook.com Follow us on Twitter: twitter.com Pin with us on Pinterest: pinterest.comFrom:Buzz60Views:0 1ratingsTime:01:07More inScience Technology
Go here to read the rest:
Decrease Cancer Risk By Eating Rainbow Of Fruits, Vegetables - Video
Alfredo Quinones-Hinojosa: How I Became a Scientist
At age 19, Quiones-Hinojosa jumped the fence from Mexico to become a farm worker in California. Thanks to his own determination, hard work and discipline and a lot of support from family and friends, he left farm work, completed university and medical school, and ultimately became a highly successful physician-scientist and brain surgeon. About the speaker: Alfredo Quiones-Hinojosa is an Associate Professor of Neurosurgery and Oncology, Neuroscience and Cellular and Molecular Medicine and Director of the Brain Tumor Surgery Program at Johns Hopkins University. As well as being an expert surgeon, he researches the role of stem cells both in causing brain tumors and potentially in fighting them. This talk was first released in iBioMagazine Issue 5.From:ibiomagazineViews:5 0ratingsTime:15:32More inScience Technology
Visit link:
Advice for This Gorilla Who Farted
Someone posted a video on the Internet of you farting. Remember this guy? He was once a part of some really important research at Harvard Medical School, but all anyone remembers him as is...well, you know. Anyway, we #39;re just writing to offer some advice on how to handle this delicate situation. Don #39;t cite the whoever-smelt-it-dealt-it rule. Never works. Always....um...backfires. Also, you might be tempted to blame this, but again, we caution you to tread lightly. Mac fanatics shoot to kill. Probably the best way to handle this is to take a cue from someone whose name is synonymous with grace and dignity. For more of the best, new videos from around the world and the stories behind them, go to RightThisMinute.com.From:RightThisMinuteViews:0 0ratingsTime:01:36More inPeople Blogs
See the article here:
POA Patient Profile: Amanda - Hemipelvectomy Amputee
Amanda was just finishing her first year of medical school when she was diagnosed with a large osteochondroma sarcoma in her pelvis. After efforts to treat and stop the progression of the disease failed, her doctors had no choice but to perform a hemipelvectomy (through the pelvis) amputation. Amanda #39;s surgeon used an experimental procedure where the thigh muscles are packed into the pelvic region, leaving all nerves and blood vessels intact. The procedure was successful, leaving Amanda with a good padding of muscle at the amputation site which not only allows her to sit more comfortably, but provides a good surface for her prosthetic limb. To view more videos and read the inspiring stories of other POA patients, please visit our website at http://www.poacfl.com or our Facebook page httpsFrom:POACFLViews:4 0ratingsTime:02:42More inPeople Blogs
See original here:
POA Patient Profile: Amanda - Hemipelvectomy Amputee - Video
Being of Service to Others: The Honored Position
http://www.sacredlearning.org Shaykh Husain Abdul Sattar Shaykh Husain [may Allah preserve him] was born in Chicago (USA) in 1972. After completing his primary education at schools in his hometown near Chicago, he joined the University of Chicago where he studied Biology, Arabic and Islamic Civilization. It was during this period that he began his study of sacred knowledge, studying Arabic grammar (nahw), Hanafi Fiqh and Usul al-Fiqh under ulama (scholars) in Chicago. In 1994 Shaykh Husain also began training in Islamic spirituality under Shaykh Zulfiqar Ahmad, a leading shaykh in this field. After obtaining his undergraduate degree, Shaykh Husain enrolled in the Pritzker School of Medicine at the University of Chicago. Along with his medical studies, he continued his studies of sacred knowledge. In his final year he took leave from medical school to focus on his religious studies, traveling to Syria and then Pakistan, where he studied a traditional curriculum for a number of years under some of their greatest scholars. Throughout his years of study, Shaykh Husain continued his training under Shaykh Zulfiqar Ahmad. He was blessed with the close company of his Shaykh, learning the science of the purification of the heart. The deep taqwa and firm adherence to the sunnah and Shariah that characterized his teacher were eventually transferred to the student and Shaykh Husain was formally authorized in this science by Shaykh Zulfiqar in July 2001. Shaykh Husain has completed medical ...From:strivingmuslim1Views:0 0ratingsTime:15:15More inEducation
Original post:
Chronicles of medical school
Giving people insight to life in medical school and the daily struggles and rollercoaster rides that ensue.From:Andres PiscoyaViews:1 0ratingsTime:05:05More inPeople Blogs
See the article here:
Body and Soul - Overcoming Depression
http://www.sacredlearning.org Shaykh Husain Abdul Sattar Shaykh Husain [may Allah preserve him] was born in Chicago (USA) in 1972. After completing his primary education at schools in his hometown near Chicago, he joined the University of Chicago where he studied Biology, Arabic and Islamic Civilization. It was during this period that he began his study of sacred knowledge, studying Arabic grammar (nahw), Hanafi Fiqh and Usul al-Fiqh under ulama (scholars) in Chicago. In 1994 Shaykh Husain also began training in Islamic spirituality under Shaykh Zulfiqar Ahmad, a leading shaykh in this field. After obtaining his undergraduate degree, Shaykh Husain enrolled in the Pritzker School of Medicine at the University of Chicago. Along with his medical studies, he continued his studies of sacred knowledge. In his final year he took leave from medical school to focus on his religious studies, traveling to Syria and then Pakistan, where he studied a traditional curriculum for a number of years under some of their greatest scholars. Throughout his years of study, Shaykh Husain continued his training under Shaykh Zulfiqar Ahmad. He was blessed with the close company of his Shaykh, learning the science of the purification of the heart. The deep taqwa and firm adherence to the sunnah and Shariah that characterized his teacher were eventually transferred to the student and Shaykh Husain was formally authorized in this science by Shaykh Zulfiqar in July 2001. Shaykh Husain has completed medical ...From:strivingmuslim1Views:0 0ratingsTime:24:49More inEducation
See more here:
LYNN — Police and hospital officials said emergency personnel and a medical helicopter landing at Breed Middle School Tuesday evening was not due to any incident at the school but because Union Hospital needed to transport a patient.
Read more from the original source:
University of Massachusetts President Robert L. Caret warned today that UMassand#8211; including the medical school in Worcester and#8211; could lose $32 million in research funding if federal lawmakers and the president fail to reach a deal to avoid the fiscal cliff.
More: